1 recruiting, 1 terminated. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
Follow VMBP protocol: new trials by email Literature Review of VMBP protocol trials Research Report on VMBP protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma Cabo + Dostarlimab - Gynecologic Cancer, Carcinoma | Phase 1 / Phase 2 | Recruiting | University of Alabama at Birmingham | 37 | 2023-08-20 | 2026-04-15 |
| Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Batiraxcept, Cabozantinib (Cabo), Nivolumab - Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Aravive, Inc. | 72 | 2021-02-26 | 2023-10-30 |
Carcinoma (1) · Carcinoma, Renal Cell (1) · Endometrial Neoplasms (1) · Kidney Diseases (1) · Kidney Neoplasms (1) · Urologic Neoplasms (1) · Uterine Neoplasms (1)
Aravive, Inc. (1) · University of Alabama at Birmingham (1)
United States (2)